Progress of chronic obstructive pulmonary disease patients with different muscle mass levels
10.3969/j.issn.1006-2483.2024.01.022
- VernacularTitle:慢性阻塞性肺疾病患者的肌肉量水平对病情进展的影响
- Author:
Xinwei LU
1
;
Haitian LI
2
;
Jing WANG
3
;
Liping HOU
1
Author Information
1. Nutrition Department of Hengshui People's Hospital , Hengshui , Hebei 053000 , China
2. Infection Department of Hengshui People's Hospital , Hengshui , Hebei 053000 , China
3. Department of Respiratory and Critical Care , Hengshui People's Hospital , Hengshui , Hebei 053000 , China
- Publication Type:Journal Article
- Keywords:
Muscle mass;
Chronic obstructive pulmonary disease;
Disease progression;
Body fat percentage;
Vitamin D
- From:
Journal of Public Health and Preventive Medicine
2024;35(1):96-99
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the difference of the disease progression in patients with chronic obstructive pulmonary disease (COPD) with different muscle mass levels and the influence of related factors on the disease progression. Methods A total of 308 newly diagnosed patients with COPD from February 2021 to February 2022 were selected for this study. All patients were below moderate COPD. The patients were divided into two groups according to their muscle mass levels: sarcopenia group (98 cases) and control group (210 cases). The diagnostic criteria for sarcopenia were based on sarcopenia diagnostic thresholds: RSMI <7.0kg/m2 in men and <5.4kg/m2 for women. All subjects were followed up for 4 months to observe the progress of the patient's condition. The correlation between the muscle mass level and pulmonary function level, as well as the results of 6-minute walking test and CAT score was evaluated, and the influence of muscle mass level on the patient's disease progress was analyzed. At the same time, the potential influence of related factors (body fat rate, vitamin D level, etc.) on the condition of patients with different muscle mass levels was discussed. SPSS 19.0 software was used to perform statistical analysis. Results Under the same treatment intervention, the baseline and follow-up lung function improvement levels of patients in the sarcopenia group were lower than those in the control group, and the difference was statistically significant (P<0.05). At the same time, the baseline and follow-up 6-minute walk test results of the patients in the sarcopenia group were also worse than those of the control group, and the difference was statistically significant (P<0.05). Further correlation analysis was carried out between the patient's muscle mass level and the post-treatment pulmonary function indicators and 6MWD test level. The results showed that the muscle mass level was positively correlated with several pulmonary function indicators (FEV1, FEV1% predict) and 6MWD (both P<0.05). Considering the possible influence of other factors on the control and progress of the patient's condition, the present study used follow-up CAT score results to distinguish the prognosis of the patient's condition improvement, and used improvement and non-improvement as dependent variables to analyze the influence of various potential influencing factors. The results of regression model analysis showed that lower baseline muscle mass, women, lower body fat percentage, and lower vitamin D level were the main risk factors. Conclusion Under the same treatment condition, COPD patients with different muscle mass levels improve more slowly when complicated with sarcopenia and have poor prognosis. Women, lower body fat percentage and lower vitamin D level are potential risk factors for poor prognosis.
